Plus   Neg

Stock Alert: DarioHealth Up 20%

Shares of DarioHealth Corp. (DRIO) are gaining over 20% on Wednesday morning, continuing its upward momentum from last Friday. On July 31, the company revealed that it raised over $28 million to fund growth of their digital therapeutics B2B market share.

DRIO is currently trading at $16.79, up $2.95 or 21.32%, on the Nasdaq. The shares have traded between $3.02 and $14.62 for the year-to-date period.

DarioHealth said it closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and Israel. The company received aggregate gross proceeds of around $28.6 million.

The company plans to use the proceeds to fund Dario's long term strategic operating plan, as it expands its focus from the direct-to-consumer channel to business-to-business-to-consumer channel.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT